MOTS-c Safety Information

MOTS-c is a mitochondrial-derived peptide, meaning it is encoded by mitochondrial DNA and produced naturally within the body's own mitochondria. Researchers have studied its role in metabolic regulation, insulin sensitivity, and cellular energy, largely in preclinical and animal models.

At Belle, MOTS-c is offered in compounded injectable form, prescribed when deemed clinically appropriate by a licensed healthcare provider. Please review the following important safety information before beginning treatment.

What Is MOTS-c?

MOTS-c therapy is considered an elective wellness treatment. Compounded MOTS-c is not approved by the FDA for any indication, and it has not been evaluated by the FDA for energy, metabolic health, athletic performance, or anti-aging purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

Human research on MOTS-c is early. Well-controlled clinical trials in people are limited, and the long-term safety of supplemental MOTS-c has not been established. Your provider can help you weigh what is known against what is not.

Always consult your healthcare provider before beginning any injectable regimen, especially if you have pre-existing health conditions.

Who Should Not Use MOTS-c

MOTS-c should not be used by individuals who:

Are allergic to MOTS-c or any ingredient in the formulation

Are pregnant, may become pregnant, or are breastfeeding

Have an active malignancy (cancer) without medical clearance

Are under 18 years of age

Have uncontrolled chronic illness without supervision from a licensed provider

Precautions and Warnings

Inform your provider if you have or have had:

Diabetes, prediabetes, or blood sugar dysregulation. MOTS-c has been studied for effects on insulin sensitivity and glucose metabolism, and your provider may wish to monitor blood sugar

Any history of cancer

Kidney or liver disease

Cardiovascular conditions

Thyroid or other endocrine conditions

A bleeding disorder, or you take an anticoagulant

Tell your provider about all medications and supplements you take, including any GLP-1 medication such as semaglutide or tirzepatide, insulin, or other diabetes treatments. If you compete in a tested sport, check with your sport's governing body before using any peptide therapy.

Common Side Effects

Because human data is limited, the full side effect profile of MOTS-c is not well characterized. Reported effects are generally mild, local, and temporary, and may include:

Injection site redness, swelling, or discomfort

Headache

Fatigue or changes in energy

Nausea

Dizziness or lightheadedness

If you experience any severe or prolonged symptoms, notify your provider immediately.

Serious Reactions (Rare)

In rare cases, patients may experience:

Hypersensitivity or allergic reaction

Significant changes in blood sugar levels

Worsening of pre-existing conditions

Stop treatment and seek medical attention immediately if you experience trouble breathing, chest pain, or swelling of the face, lips, or throat.

Use and Administration

Use MOTS-c only as directed by your licensed provider.

Do not exceed the prescribed dosage or frequency.

MOTS-c is administered via subcutaneous injection, on the schedule your provider sets.

Rotate injection sites to reduce the chance of local reactions.

If you miss a dose, contact your provider for guidance before resuming.

Report any adverse effects or unexpected symptoms during treatment.

Storage and Disposal

Store MOTS-c as directed on the pharmacy label, typically refrigerated and protected from light. Do not use expired products. Dispose of needles and syringes in an approved sharps container. Keep out of reach of children.